Olmesartan medoxomil/rosuvastatin compound preparation and preparation method thereof

Abstract

The invention discloses an olmesartan medoxomil / rosuvastatin compound preparation and a preparation method thereof. The olmesartan medoxomil / rosuvastatin compound preparation is characterized by being prepared from a main drug and auxiliary materials, wherein the main drug is prepared from olmesartan medoxomil and rosuvastatin; the auxiliary materials comprise filler, a disintegrating agent, an adhesive, lubricant and a flow aid; the olmesartan medoxomil / rosuvastatin compound preparation is prepared through the process steps of raw material selecting, preparation, mixing, soft material preparing, pelleting, drying, particle finishing, total blending, finished product forming and the like. Olmesartan medoxomil is an ARB antihypertensive drug, has approximately-ideal pharmacological characteristics, and has an excellent antihypertensive effect. Rosuvastatin is a blood lipid regulating drug and is suitable for primary hypercholesterolemia (IIa type, including heterozygous familial hypercholesterolemia) or hybrid dyslipidemia (IIb type) with dyslipidemia incapable of being properly controlled through diet control and other non-drug treatment (such as sports therapy and weight losing). The compound preparation is formed by olmesartan medoxomil and rosuvastatin and is more suitable for treating patients with cardiovascular diseases, and the compliance of the patients is improved.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to an olmesartan medoxomil / rosuvastatin compound preparation and a preparation method thereof. Background technique [0002] Cardiovascular and cerebrovascular diseases are collectively referred to as cardiovascular diseases and cerebrovascular diseases. Generic name for disease. [0003] Cardiovascular and cerebrovascular diseases are a common disease that seriously threatens the health of human beings, especially middle-aged and elderly people over 50 years old. Even if the most advanced and perfect treatment methods are applied, more than 50% of survivors of cerebrovascular accidents still cannot fully live. Take care of yourself! The number of people who die from cardiovascular and cerebrovascular diseases in the world is as high as 15 million every year, ranking first among various causes of death. Cardiovascular and cerebrovascular diseases have become the number one kill...

AI Technical Summary

Problems solved by technology

[0009]Currently, most of the drugs used to treat cardiovascular diseases can only achieve a better state of stabilizing and controlling blood pressure, but cannot clean blood lipids well or reduce blood thickening etc., and the patient's compliance with the drug is not good, which cannot meet the market demand